

Alkem MedTech to acquire majority stake in Swiss firm Occlutech Holding for Rs 1074 Cr

13 February 2026 | News

Acquisition is expected to be completed by June 2026 after the regulatory approvals are obtained



Alkem MedTech, a wholly-owned medical devices subsidiary of Alkem Laboratories, has announced the execution of a binding offer for acquiring a majority stake in Occlutech Holding AG, a global medical devices company, headquartered in Switzerland, specialising in minimally invasive cardiac implants.

Alkem MedTech intends to buy up to 55% stake in Occlutech for a consideration of EUR 99.4 million (Approx. Rs 1,074 crore), subject to statutory approvals. This acquisition represents a significant step in Alkem MedTech's journey to build a global footprint and enables its entry into advanced cardiovascular devices.

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure. Occlutech is the second-largest company in Europe in the minimally invasive cardiac implants segment and the third-largest globally. It operates manufacturing and R&D facilities in Germany and Turkey, a global distribution hub in Sweden, and clinical operations in the US.

In calendar year 2025, Occlutech recorded a revenue of EUR 49.4 million (unaudited), representing a 15.7% CAGR over the past three years. Occlutech derives about 85% of its revenue from Europe and the US.

The transaction remains subject to entering into definitive agreements, company's conditions precedent to be fulfilled, authorisation by the statutory authority as part of the control of foreign investments in some of the geographies, as well as the absence of qualified material adverse events. The acquisition is expected to be completed by June 2026 after the regulatory approvals are obtained.